Aesthetic Plastic Surgery

, Volume 43, Issue 6, pp 1657–1662 | Cite as

Effect of a Formulation Containing Low-Dose Sodium Deoxycholate on Local Fat Reduction

  • Sang Hoon Park
  • Mi Ri Hyun
  • Sang Wha KimEmail author
Original Article Basic Science/Experimental



Synthetic deoxycholic acid (DCA) has been approved as an injectable drug for the nonsurgical reduction of submental fat.


In this study, we evaluated the fat-reducing effects of a new formula containing a low dose of DCA and fat dissolution by topical application of DCA.


Sodium deoxycholate (99.1% pure) and the new formulation containing 10% DCA were injected or topically applied to the dorsa of obese mice (induced by a high-fat diet). The rate of change in body weight was evaluated, together with comparisons of micro-computed tomography images, body composition measurements, and histology findings.


The results showed that the new formula containing low-dose DCA was as effective as the older high-dose formulation with respect to the rate of change in body weight and reductions in subcutaneous fat pad area, body fat weight, and the thickness of the subcutaneous fat layer. Furthermore, topical application of the high-dose, but not the low-dose, formulation yielded promising effects.


The development of a better protocol for the high-dose preparation, including dose optimization and application methods that minimize the adverse effects of DCA, merits further study.

No Level Assigned

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine Ratings, please refer to Table of Contents or online Instructions to Authors - .


Deoxycholate Lipolysis Subcutaneous fat 


Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest to disclose.

Human and Animal Rights

The animal care and experimental procedures were approved by the Institutional Animal Care and Use Committee.

Informed Consent

For this type of study, informed consent is not required.


  1. 1.
    Ginsberg HN, MacCallum PR (2009) The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr 4:113–119CrossRefGoogle Scholar
  2. 2.
    Kim JY, Kwon MS, Son J, Kang SW, Song Y (2017) Selective effect of phosphatidylcholine on the lysis of adipocytes. PLoS ONE 12:e0176722CrossRefGoogle Scholar
  3. 3.
    Seretis K, Goulis DG, Koliakos G, Demiri E (2015) Short-and long-term effects of abdominal lipectomy on weight and fat mass in females: a systematic review. Obes Surg 25:1950–1958CrossRefGoogle Scholar
  4. 4.
    Georgesen C, Lipner SR (2017) The development, evidence, and current use of ATX-101 for the treatment of submental fat. J Cosmet Dermatol 16:174–179CrossRefGoogle Scholar
  5. 5.
    Humphrey S, Beleznay K, Beleznay JD (2016) Sodium deoxycholate for submental contouring. Skin Ther Lett 21:1–4Google Scholar
  6. 6.
    Tierney EP, Kouba DJ, Hanke CW (2011) Safety of tumescent and laser-assisted liposuction: review of the literature. J Drugs Dermatol 10:1363–1369PubMedGoogle Scholar
  7. 7.
    Bechara FG, Sand M, Hoffmann K, Sand D, Altmeyer P, Stücker M (2007) Fat tissue after lipolysis of lipomas: a histopathological and immunohistochemical study. J Cutan Pathol 34:552–557CrossRefGoogle Scholar
  8. 8.
    Rotunda AM, Suzuki H, Moy RL, Kolodney MS (2004) Detergent effects of sodium deoxycholate are a major feature of an injectable phosphatidylcholine formulation used for localized fat dissolution. Dermatol Surg 30:1001–1008PubMedGoogle Scholar
  9. 9.
    Thuangtong R, Bentow JJ, Knopp K, Mahmood NA, David NE, Kolodney MS (2010) Tissue-selective effects of injected deoxycholate. Dermatol Surg 36:899–908CrossRefGoogle Scholar
  10. 10.
    Rotunda AM, Ablon G, Kolodney MS (2005) Lipomas treated with subcutaneous deoxycholate injections. J Am Acad Dermatol 53:973–978CrossRefGoogle Scholar
  11. 11.
    Humphrey S, Sykes J, Kantor J, Bertucci V, Walker P, Lee DR, Lizzul PF, Gross TM, Beddingfield FC 3rd (2016) ATX-101 for reduction of submental fat: a phase III randomized controlled trial. J Am Acad Dermatol 75:788–797CrossRefGoogle Scholar
  12. 12.
    Reeds DN, Mohammed BS, Klein S, Boswell CB, Young VL (2013) Metabolic and structural effects of phosphatidylcholine and deoxycholate injections on subcutaneous fat: a randomized, controlled trial. Aesthet Surg J 33:400–408CrossRefGoogle Scholar
  13. 13.
    Duncan D, Rotunda AM (2011) Injectable therapies for localized fat loss: state of the art. Clin Plast Surg 38:489–501CrossRefGoogle Scholar
  14. 14.
    Salti G, Ghersetich I, Tantussi F, Bovani B, Lotti T (2008) Phosphatidylcholine and sodium deoxycholate in the treatment of localized fat: a double-blind, randomized study. Dermatol Surg 34:60–66CrossRefGoogle Scholar
  15. 15.
    Gupta A, Lobocki C, Singh S, Robertson M, Akadiri OA, Malhotra G, Jackson IT (2009) Actions and comparative efficacy of phosphatidylcholine formulation and isolated sodium deoxycholate for different cell types. Aesthet Plast Surg 33:346–352CrossRefGoogle Scholar
  16. 16.
    Duncan D (2013) Commentary on: Metabolic and structural effects of phosphatidylcholine and deoxycholate injections on subcutaneous fat: a randomized, controlled trial. Aesthet Surg J 33:411–413CrossRefGoogle Scholar
  17. 17.
    Dayan SH, Humphrey S, Jones DH, Lizzul PF, Gross TM, Stauffer K, Beddingfield FC 3rd (2016) Overview of ATX-101 (deoxycholic acid injection): a nonsurgical approach for reduction of submental fat. Dermatol Surg 42(Suppl 1):S263–S270CrossRefGoogle Scholar
  18. 18.
    Walker P, Fellmann J, Lizzul PF (2015) A phase I safety and pharmacokinetic study of ATX-101: injectable, synthetic deoxycholic acid for submental contouring. J Drugs Dermatol 14:279–287PubMedGoogle Scholar
  19. 19.
    Rzany B, Griffiths T, Walker P, Lippert S, McDiarmid J, Havlickova B (2014) Reduction of unwanted submental fat with ATX-101 (deoxycholic acid), an adipocytolytic injectable treatment: results from a phase III, randomized, placebo-controlled study. Br J Dermatol 170:445–453CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature and International Society of Aesthetic Plastic Surgery 2019

Authors and Affiliations

  1. 1.Department of Plastic SurgeryId HospitalSeoulRepublic of Korea
  2. 2.Department of Plastic and Reconstructive Surgery, College of MedicineSeoul National University, Seoul National University HospitalSeoulRepublic of Korea

Personalised recommendations